全球抗癌药物市场规模（按产品、应用、地区、范围和预测）

抗癌药物的市场规模及预测

抗肿瘤药物市场规模预计在2023 年达到1257.1 亿美元，预计在2024 年至2030 年期间将以7.1% 的复合年增长率增长，到2030 年将达到2854.9 亿美元。达到美国10万美元。

抗肿瘤药物的全球市场推动因素

抗癌药物市场的市场推动因素会受到多种因素的影响。

癌症发生率不断上升：

抗癌药物市场受到全球癌症发生率上升的显着影响。由于人口老化、生活方式改变和环境因素导致的癌症发生率上升，对有效的癌症治疗方法（包括抗肿瘤药物）的需求也随之增加。

癌症研究的进展：

随着癌症分子生物学原因的阐明和个人化治疗方法的发展，抗癌药物的市场正在不断扩大。与传统化疗相比，标靶疗法副作用更小、治疗更有针对性，因此其使用率更高，市场也越来越大。

技术进步：

随着药物传递系统的进步，包括脂质体、奈米颗粒和定製药物传递平台，抗癌药物的安全性和有效性得到了提高。这些技术发展透过改善患者体验和治疗结果来支持市场发展。

增加医疗支出：

医疗保健支出的增加推动了包括抗癌药物在内的尖端癌症治疗方法的采用，尤其是在发展中国家。患者知识的提高、保险覆盖范围的扩大和政府的措施都有助于使这些治疗更容易获得。

管道开发：

市场扩张的动力来自于大量针对各种癌症的创新肿瘤药物。製药公司和学术机构正在透过开发和测试新药物和治疗方案不断增加治疗选择的范围。

改善治疗效果：

由于个人化医疗的趋势，针对性抗癌药物的需求很高，在个人化医疗中，治疗计画会考虑到患者的遗传和肿瘤生物标记等特征。随着个人化技术改善治疗效果并减少副作用，市场正在扩大。

监理支援：

旨在加速药物开发的监管计划促进了肿瘤药物的市场开发。此类措施的例子包括加快审批流程和孤儿药分类激励措施。良好的监管框架将促进新药的快速商业化，并有助于扩大市场。

老化世界：

由于人口老化，对抗癌药物的需求不断增加，这导致癌症发生率不断上升，尤其是在工业化国家。老化趋势导致癌症风险增高，推高了治疗费用，扩大了市场规模。

新兴经济体：

拉丁美洲、非洲和亚太地区的新兴国家肿瘤药物市场具有巨大的成长空间。在这些地区，由于可支配收入增加、城市化快速发展和医疗保健基础设施改善等因素，晚期癌症治疗变得越来越普遍。

伙伴关係与合作关係：

製药公司、学术机构和医疗机构共同合作推动药物开发和商业化措施将加速市场发展。此次合作将促进资讯共享、资源共享和技术互补，进而提高肿瘤药物在市场上的竞争力。

限制全球抗癌药物市场的因素

有几个因素可能会对抗肿瘤药物市场造成市场限製或课题。这些包括：

严格的法律：

严格的立法：管理肿瘤药物行销和批准的严格立法可能会导致製造商推出新产品的时间延迟和成本增加。

开发成本高：

开发新型抗癌药物需要大量的研究和开发，而且成本很高。此外，临床试验的失败率进一步增加了製药公司的成本。

专利已过期：

当主要肿瘤药物的专利到期后，仿製药可能会进入市场，从而压低价格并减少品牌药厂商的市场占有率。

副作用：

抗肿瘤药物虽然有效，但常产生噁心、呕吐、掉髮、免疫抑制等严重副作用。对这些副作用的担忧可能会限制医生的处方率和患者的依从性。

抗药性发展：

随着时间的推移，肿瘤细胞可能会对抗癌药物产生抗药性，从而降低目前疗法的有效性并需要开发新的治疗方法。

限制获得医疗保健的机会：

在某些地区，特别是发展中国家，由于缺乏医疗设施和治疗费用过高，患者获得抗癌药物的机会可能会受到限制。

技术难题：

开发安全性和疗效较佳的新型抗癌药物在技术上极具课题性，需要大量的研发成本。

与替代疗法竞争：

免疫疗法和标靶疗法是癌症治疗中两种越来越受欢迎的替代疗法。传统抗肿瘤药物可能面临这些替代疗法的竞争，因为它们的疗效和可用性不断提高。

目录

第 1 章全球肿瘤药物市场：简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第四章 抗癌药物全球市场展望

• 概述
• 市场动态
• 驱动程式
• 阻碍因素
• 机会
• 波特五力模型
• 价值链分析

5. 全球抗肿瘤药物市场（依产品划分）

• 概述
• 化疗药物
• 生物/免疫治疗剂
• 个人化医疗

6. 全球抗肿瘤药物市场（依应用）

• 概述
• 医院
• 诊所
• 癌症復健中心
• 门诊手术中心

7. 全球抗肿瘤药物市场（按地区）

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 德国
• 英国
• 法国
• 其他欧洲国家 亚太地区
• 中国
• 日本
• 印度
• 其他亚太地区
• 世界其他地区
• 拉丁美洲
• 中东和非洲

第 8 章。

• 概述
• 各公司的市场排名
• 主要发展策略

第九章 公司简介

• Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb Company
• Baxter
• Boehringer Ingelheim
• Bayer
• Teva pharmaceutical Industries
• Johnson & Johnson
• Merck
• Pfize
• Accord Healthcare
• Lundbeck
• AbbVie

第 10 章附录

• 相关报告

Anti-Neoplastic Agents Market Size And Forecast

Anti-Neoplastic Agents Market size was valued at USD 125.71 Billion in 2023 and is projected to reach USD 285.49 Billion by 2030 , growing at a CAGR of 7.1% during the forecasted period 2024 to 2030.

Global Anti-Neoplastic Agents Market Drivers

The market drivers for the Anti-Neoplastic Agents Market can be influenced by various factors. These may include:

Growing Cancer Incidence:

The market for anti-neoplastic agents is significantly influenced by the rising incidence of cancer worldwide. The need for efficient cancer treatments, such as anti-neoplastic drugs, is increasing as cancer rates rise as a result of ageing populations, changing lifestyles, and environmental factors.

Progress in Cancer Research:

The market for anti-neoplastic drugs is expanding due to ongoing efforts to better understand the molecular causes of cancer and to develop tailored treatments. Compared to conventional chemotherapy, targeted therapies provide more focused treatment options with fewer side effects, which has improved usage and expanded the market.

Technological Advancements:

The safety and effectiveness of anti-neoplastic drugs are improved by advances in drug delivery systems, including as liposomes, nanoparticles, and tailored drug delivery platforms. Through bettering patient experiences and treatment outcomes, these technology developments support market expansion.

Growing Healthcare Expenditure:

The adoption of cutting-edge cancer treatments, such as anti-neoplastic drugs, is supported by rising healthcare spending, especially in developing nations. Increased patient knowledge, insurance coverage expansions, and government initiatives all help to make these treatments more accessible.

Pipeline Development:

The market's expansion is fueled by a strong pipeline of innovative anti-neoplastic drugs that target different types of cancer. The variety of therapeutic alternatives is constantly being increased by pharmaceutical corporations and academic institutions through the development and testing of novel substances and treatment regimens.

Improved Treatment Outcomes:

Targeted anti-neoplastic drugs are in high demand due to the trend towards personalized medicine, in which patient features such as genetic makeup and tumor biomarkers are taken into account when designing a treatment plan. The market is expanding because personalized techniques result in better treatment outcomes and fewer side effects.

Regulatory Support:

Market access for anti-neoplastic drugs is facilitated by regulatory programmes that aim to accelerate drug development. Examples of these initiatives include faster approval processes and incentives for orphan drug classification. Promising regulatory frameworks facilitate the expeditious commercialization of novel medicines, hence propelling market expansion.

Global Ageing Population:

The need for anti-neoplastic medications is driven by the ageing population, especially in industrialized nations where it is a contributing factor to the rising incidence of cancer. Due to their increased cancer risk, older persons are driving up treatment costs and expanding the market.

Emerging Economies:

The market for anti-neoplastic drugs has enormous room to grow in emerging economies in Latin America, Africa, and Asia-Pacific. Advanced cancer treatments are more widely accessible in these areas due to factors like rising disposable incomes, rapid urbanization, and improved healthcare infrastructure.

Partnerships and Collaborations:

Pharmaceutical corporations, academic institutions, and healthcare organizations work together to expedite medication development and commercialization initiatives, which in turn spurs market expansion. Partnerships increase the competitiveness of anti-neoplastic agents in the market by facilitating information sharing, resource sharing, and access to complementary technologies.

Global Anti-Neoplastic Agents Market Restraints

Several factors can act as restraints or challenges for the Anti-Neoplastic Agents Market. These may include:

Strict laws:

Manufacturers may have difficulties as a result of the strict laws governing the marketing and approval of anti-neoplastic drugs, which could cause delays in the launch of new products and higher expenses.

High Development Costs:

Developing novel anti-neoplastic drugs requires a significant amount of research and development, which can be expensive. Furthermore, the cost burden on pharmaceutical businesses is further increased by the failure rate in clinical trials.

Patent Expiration:

When major anti-neoplastic medications' patents expire, generic competitors might join the market, driving down prices and eroding market share for the original producers.

Side Effects:

Anti-neoplastic drugs, although effective, frequently have serious side effects such as nausea, vomiting, hair loss, and immunosuppression. Physician prescription rates and patient compliance may be restricted due to worries about these negative effects.

Resistance Development:

Over time, tumor cells may become resistant to anti-neoplastic drugs, which will decrease the efficacy of current therapies and call for the creation of new ones.

Limited Access to Healthcare:

In certain areas, especially in developing nations, patients' access to anti-neoplastic drugs may be restricted by a lack of access to healthcare facilities and excessive treatment expenses.

Technological Difficulties:

Creating novel anti-neoplastic drugs with enhanced safety and efficacy profiles presents technological difficulties that call for hefty expenditures in R&D.

Competition from Alternative Therapies:

Immunotherapy and targeted therapy are two alternative therapies that are becoming more and more popular in the treatment of cancer. Traditional anti-neoplastic drugs may face competition from these alternatives due of their growing efficacy and availability.

Global Anti-Neoplastic Agents Market Segmentation Analysis

The Global Anti-Neoplastic Agents Market is segmented on the basis of Product, Application, And Geography.

Anti-Neoplastic Agents Market, By Product

• Chemotherapeutic Agents
• Biological/Immunotherapeutic Agents
• Personalized Medicine

Based on the Product, the market is bifurcated into Chemotherapeutic Agents Biological/Immunotherapeutic Agents and Personalized Medicine. Chemotherapeutic agents are predicted to hold the largest market share due to the ease of availability of drugs. Immunotherapeutic agents will grow with the highest CAGR owing to the growing acceptance of biological therapy as they have lesser side effects.

Anti-Neoplastic Agents Market, By Application

• Hospitals
• Clinics
• Cancer Rehabilitation Centers
• Ambulatory Surgical Centers

Based on the Application, the market is bifurcated into Hospitals, Clinics, Cancer Rehabilitation Centers, and Ambulatory Surgical Centers. Hospitals are anticipated to hold the maximum share as there is a vast number of cancer patients hospitalized in the hospitals every year. As per the statistics given by The Healthcare Cost and Utilization Project (H-cup), there were 4.7 Mn hospitalizations related to cancer in the U.S. in the year 2009 and about 6% of adult inpatient hospital cost was generated by the hospitalization of cancer patients.

Anti-Neoplastic Agents Market, By Geography

• North America
• Europe
• The Asia Pacific
• Rest of the world
• On the basis of Regional Analysis, the Global Anti-Neoplastic Agents Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America will continue to dominate the global Anti-Neoplastic Agents Market due to the high prevalence of malignant neoplasm. Europe is expected to hold the second-largest market share in the global Anti-Neoplastic Agents Market. In 2013, as per Cancer Research UK, 605 people per 100,000 general population were diagnosed with cancer.

Key Players

• Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb Company
• Baxter
• Boehringer Ingelheim
• Bayer
• Teva Pharmaceutical Industries
• Johnson & Johnson
• Merck
• Pfizer
• Accord Healthcare
• Lundbeck
• AbbVie

TABLE OF CONTENTS

1. Introduction of Global Anti-Neoplastic Agents Market

• Overview of the Market
• Scope of Report
• Assumptions

2. Executive Summary

3. Research Methodology of Verified Market Research

• Data Mining
• Validation
• Primary Interviews
• List of Data Sources

4. Global Anti-Neoplastic Agents Market Outlook

• Overview
• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Porters Five Force Model
• Value Chain Analysis

5. Global Anti-Neoplastic Agents Market, By Product

• Overview
• Chemotherapeutic Agents
• Biological/Immunotherapeutic Agents
• Personalized Medicine

6. Global Anti-Neoplastic Agents Market, By Application

• Overview
• Hospitals
• Clinics
• Cancer Rehabilitation Centers
• Ambulatory Surgical Centers

7. Global Anti-Neoplastic Agents Market, By Geography

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• Rest of the World
• Latin America
• Middle East & Africa

8. Global Anti-Neoplastic Agents Market Competitive Landscape

• Overview
• Company Market Ranking
• Key Development Strategies

9. Company Profiles

• Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb Company
• Baxter
• Boehringer Ingelheim
• Bayer
• Teva pharmaceutical Industries
• Johnson & Johnson
• Merck
• Pfize
• Accord Healthcare
• Lundbeck
• AbbVie

10. Appendix

• Related Reports